Do Analysts Agree Wednesday on CTI BioPharma Corp (CTIC) Stock's Target Price?

Wednesday, May 31, 2023 03:53 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Agree Wednesday on CTI BioPharma Corp (CTIC) Stock's Target Price?

Analysts who follow CTI BioPharma Corp (CTIC) on average expect it to increase 15.96% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns the stock an Analyst Ranking of 20, which means it ranks higher than 20 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating CTIC a Buy today. Find out what this means to you and get the rest of the rankings on CTIC!

See Full CTIC Report

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With CTI BioPharma Corp Stock Today?

CTI BioPharma Corp (CTIC) stock is higher by 0.11% while the S&P 500 is lower by -0.33% as of 3:46 PM on Wednesday, May 31. CTIC has risen $0.01 from the previous closing price of $9.02 on volume of 1,687,646 shares. Over the past year the S&P 500 is higher by 1.44% while CTIC has risen 66.30%. CTIC lost -$0.58 per share the over the last 12 months. Click Here to get the full Stock Report for CTI BioPharma Corp stock.